Clinical Observation And Mechanism Of Yiqi Huoxue Jiedu Decoction In The Treatment Of Advanced Ovarian Cancer

This essay mainly includes 2 dimensions of clinical and experimental study of the Yiqi Huoxue Jiedu Decoction for the treatment of advanced ovarian cancer.Part 1.The clinical research of Yiqi Huoxue Jiedu Decoction treating advanced ovarian cancerObjective:To study on the clinical effect of Yiqi Huoxue Jiedu Decoction treating advanced ovarian cancer.Methods:There were 104 cases enrolled totally,all of whom were IIIc to IV phase epithelial ovarian cancer.Patients enrolled from Guang’anmen Hospital received Yiqi Huoxue Jiedu Decoction(n=53),and participants enrolled from the Second Hospital of Hebei Medical University took Fufangbanmao capsules.All subjects were asked to finish questionnaires about Functional Assessment of Cancer Therapy-Ovary cancer(FACT-O)and Traditional Chinese Medicine(TCM)syndromes.The primary endpoint was the progression free survival(PFS),and the second endpoint was the score of FACT-O and TCM syndromes.All the research data was disposed with SPSS 23.0.Results:1.Comparison of PFS:The median PFS of treatment group was 22 months,while in control group was 18 months.Kaplan-Meier showed Yiqi Huoxue Jiedu Decoction could prolong the PFS of patients(Log Rank P<0.05).2.Improvement of quality of life:Both groups showed improvement in quality of life.After 6 months’ treatment,patients in control group has promoted their physical status(P<0.05),whereas there was no significant promotion in social/family status,emotional status,functional status and additional items(P>0.05).In treatment group,physical status,functional status and additional items had shown distinct increase(P<0.05).After 6 months’ treatments,Yiqi Huoxue Jiedu Decoction demonstrated a notable advantage against Fufangbanmao capsules in hysical status,functional status and additional items(P<0.05).3.TCM syndrome scores:Both treatment alleviated patient’s TCM syndromes.As for effective rate,treatment group was 71.70%,comparing 54.9%in control group,which showed remarkable difference(P<0.01).Conclusions:Yiqi Huoxue Jiedu Decoction can alleviate quality of life of advanced ovarian cancer,and is capable of prolonging their PFS.Part 2.Human Umbilical Vein Endothelial cells(HUVECs)angiogenesis trials.Objective:To study on the inhibitive effects of Yiqi Huoxue Jiedu Decoction on ovarian cancer ID8 cells.And by observing its influences on angiogenesis of regulatory T cells(Tregs)and anti-VEGF(Vascular Endothelial Growth Factor),explore its mechanism.Methods:1.Preparation of medicated serum;2.Recovery,cultivation and passage of ovarian cancer ID8 cells and HUVECs;3.Verify the inhibitive effect of Yiqi Huoxue Jiedu Decoction on ovarian cancer ID8 cells,using 3-(4,5)-dimethylthiahiazo(-z-yl)-3,5-di-phenytetrazoliumromide(MTT);4.Separation of Tregs by immune magnetic MACS MicroBeads;5.Human Umbilical Vein Endothelial cells(HUVECs)angiogenesis tials.Results:1.Both 10%and 20%medicated serum groups showed inhibitive impact on ID8,and the effect was most obvious at 96h.20%medicated serum groups showed significant advantages against 10%medicated serum groups at 72h(P<0.01)and 96h(P<0.05).2.Compared with Treg(-)group,HUVECs in Treg(+)group showed a better capability of movement and differentiation.Anti-VEGF and Yiqi Huoxue Jiedu Decoction can suppress the movement of HUVECs,and fewer vessels were formed.Combination of Anti-VEGF and Yiqi Huoxue Jiedu Decoction could enhance the inhibitive effects.Conclusions:Yiqi Huoxue Jiedu Decoction can suppress the proliferation of ovarian cancer ID8 cells,whose mechanism maybe relevant to anti-Tregs,and preventing angiogenesis.